These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36869710)

  • 1. Letter to the Editor From Chatelain et al: "Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial".
    Chatelain P; Kjelgaard-Hansen M; Sprogøe K
    J Clin Endocrinol Metab; 2023 Jul; 108(8):e644-e645. PubMed ID: 36869710
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to Letter to the Editor From Chatelain et al: "Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial".
    Miller BS; Blair JC; Rasmussen MH; Maniatis A; Kildemoes RJ; Mori J; Polak M; Bang RB; Böttcher V; Stagi S; Horikawa R
    J Clin Endocrinol Metab; 2023 Jul; 108(8):e647-e648. PubMed ID: 36869702
    [No Abstract]   [Full Text] [Related]  

  • 3. Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial.
    Miller BS; Blair JC; Rasmussen MH; Maniatis A; Kildemoes RJ; Mori J; Polak M; Bang RB; Böttcher V; Stagi S; Horikawa R
    J Clin Endocrinol Metab; 2022 Nov; 107(12):3378-3388. PubMed ID: 36062966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial.
    Mori J; Ohata Y; Fujisawa Y; Sato Y; Röhrich S; Rasmussen MH; Bang RB; Horikawa R
    Clin Endocrinol (Oxf); 2024 Apr; 100(4):389-398. PubMed ID: 38368603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH.
    Miller BS; Blair JC; Rasmussen MH; Maniatis A; Mori J; Böttcher V; Kim HS; Bang RB; Polak M; Horikawa R
    J Clin Endocrinol Metab; 2023 Nov; 108(12):3090-3099. PubMed ID: 37406251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial.
    Johannsson G; Gordon MB; Højby Rasmussen M; Håkonsson IH; Karges W; Sværke C; Tahara S; Takano K; Biller BMK
    J Clin Endocrinol Metab; 2020 Apr; 105(4):e1358-76. PubMed ID: 32022863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
    Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial.
    Sävendahl L; Battelino T; Brod M; Højby Rasmussen M; Horikawa R; Juul RV; Saenger P;
    J Clin Endocrinol Metab; 2020 Apr; 105(4):e1847-61. PubMed ID: 31917835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial.
    Johannsson G; Feldt-Rasmussen U; Håkonsson IH; Biering H; Rodien P; Tahara S; Toogood A; Rasmussen MH;
    Eur J Endocrinol; 2018 May; 178(5):491-499. PubMed ID: 29500310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency.
    Garner T; Clayton P; Højby M; Murray P; Stevens A
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1214-1221. PubMed ID: 38066644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3.
    Sävendahl L; Battelino T; Højby Rasmussen M; Brod M; Saenger P; Horikawa R
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1357-1367. PubMed ID: 34964458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3.
    Sävendahl L; Battelino T; Højby Rasmussen M; Brod M; Röhrich S; Saenger P; Horikawa R
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2569-2578. PubMed ID: 36995872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone.
    Otsuka F; Takahashi Y; Tahara S; Ogawa Y; Højby Rasmussen M; Takano K
    Clin Endocrinol (Oxf); 2020 Nov; 93(5):620-628. PubMed ID: 32603494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency.
    Takahashi Y; Biller BMK; Fukuoka H; Ho KKY; Rasmussen MH; Nedjatian N; Sværke C; Yuen KCJ; Johannsson G
    Pituitary; 2023 Feb; 26(1):57-72. PubMed ID: 36380045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency.
    Kildemoes RJ; Hollensen C; Biller BMK; Johannsson G; Takahashi Y; Rasmussen MH
    Eur J Endocrinol; 2022 May; 187(1):27-38. PubMed ID: 35521713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter to the Editor From Sävendahl et al.: "Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial".
    Sävendahl L; Battelino T; Brod M; Højby Rasmussen M; Juul Kildemoes R; Saenger P
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e888-e889. PubMed ID: 34626473
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to Letter to the Editor From L. Sävendahl et al: "Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial".
    Thornton PS; Maniatis AK; Aghajanova E; Chertok E; Vlachopapadopoulou E; Lin Z; Song W; Christoffersen ED; Breinholt VM; Kovalenko T; Giorgadze E; Korpal-Szczyrska M; Hofman PL; Karpf DB; Shu AD; Beckert M
    J Clin Endocrinol Metab; 2022 Feb; 107(3):e1333-e1334. PubMed ID: 34626470
    [No Abstract]   [Full Text] [Related]  

  • 18. Somapacitan: a long-acting growth hormone derivative for treatment of growth hormone deficiency.
    Paton DM
    Drugs Today (Barc); 2022 Oct; 58(10):509-517. PubMed ID: 36305544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials.
    Bentz Damholt B; Dombernowsky SL; Dahl Bendtsen M; Bisgaard C; Højby Rasmussen M
    Clin Pharmacokinet; 2021 Aug; 60(8):1015-1027. PubMed ID: 33754315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials.
    Juul RV; Rasmussen MH; Agersø H; Overgaard RV
    Clin Pharmacokinet; 2019 Jan; 58(1):63-75. PubMed ID: 29671202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.